NEWS

PRESS RELEASES

MAY 4, 2022

MELT-210 Top-Line Results of Phase 1 Pharmacokinetics (PK) Study

MARCH 10, 2022

Melt Pharmaceuticals Names Experienced Executive Brad Osborne as Chief Financial Officer

JANUARY 4, 2022

Melt Pharmaceuticals Submits INDs for MELT‑210 and MELT-400 to FDA

SEPTEMBER 2, 2021

Harrow Health Provides $13.5 Million Senior Secured Loan to Melt Pharmaceuticals

FEBRUARY 9, 2021

Melt Pharmaceuticals Completes Phase 1 Study for Sublingual, Non-Opioid Pain and Sedation Drug Candidate

JULY 30, 2020

Melt Pharmaceuticals Enters the Clinical Stage of MELT-100 Development

FEBRUARY 13, 2019

Melt Pharmaceuticals Improves Patent Estate for Sublingual Non-Opioid Pain and Sedation Formulations

FEBRUARY 5, 2019

Harrow Health Announces $11 Million Series A Financing for Melt Pharmaceuticals Subsidiary

MARCH 27, 2018

Imprimis Pharmaceuticals Issued Composition Patent for Non-Opioid Conscious Sedation Formulation

RELATED NEWS

CMS proposes Medicare Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System changes for 2019 (CMS-1695-P)

MORE